Publications by authors named "T W West"
Background: We aimed to investigate whether the quantitative analysis of plasma biomarkers could distinguish the pathology stages indicated by positron emission tomography (PET)-based Thal phase of amyloid and Braak stage of tau.
Method: A total of 232 participants were enrolled, all of whom underwent F-florbetaben (FBB), F-flortaucipir (FTP) PET, plasma p-tau217/np-tau217 ratio, p-tau217, and Aβ ratio. To differentiate between image-based Thal phases and Braak stages, region-of-interests (ROIs) were constructed, and cut-off points were established at each stage using Gaussian mixture modeling.
Background: We aimed to validate the ability of Alzheimer's disease plasma biomarkers to predict clinical diagnosis and the ability to predict image-based A/T/N biomarkers positivity in Asian population. We also sought to define the optimal cut point for each biomarker.
Method: 232 participants were enrolled, all of whom underwent F-florbetaben (FBB), F-flortaucipir (FTP) PET, volumetric MRI, and neuropsychological assessments.
Background: An accurate blood test for Alzheimer's disease (AD) could streamline the diagnostic work-up and treatment of AD. Our aim was to evaluate an AD blood test in primary and secondary care, using predefined biomarker cutoffs and prospective analyses of plasma samples.
Method: 940 prospective and unselected patients seeking medical evaluation for early cognitive symptoms were included.
Hemolysin co-regulated protein 1 (Hcp1) is a component of the cluster 1 Type VI secretion system (T6SS1) that plays a key role during the intracellular lifecycle of Burkholderia pseudomallei. Hcp1 is recognized as a promising target antigen for developing melioidosis diagnostics and vaccines. While the gene encoding Hcp1 is retained across B.
View Article and Find Full Text PDFObjective: To assess the diagnostic performance of a single Knee injury and Osteoarthritis Outcome Score (KOOS) item in evaluating the presence of knee crepitus.
Design: All 184 participants aged 18-40 years with a symptomatic knee, 9-36 months following anterior cruciate ligament reconstruction (ACLR) who were prospectively enrolled in a post-traumatic knee osteoarthritis trial (ACTRN12620001164987) were included. Participants completed the KOOS and underwent physical examination for knee crepitus at baseline.